Nucleic Acids Research, 1992, Vol. 20, No. 21 5691-5698
© 1992
MOLECULAR BIOLOGY |
Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity
Department of Radiation Medicine, Vincent T.Lombardi Cancer Center, Georgetown University Medical Center Washington, DC 20007, USA
Received July 22, 1992. Revised September 28, 1992. Accepted September 28, 1992.
We have studied factors which may effect the intracellular availability of oligonucleotides to achieve antisense activity. 15–20 mer unmodified, phos-phorothioate modified and liposomally encapsulated oligodeoxynucleotides have been tested in leukemia MOLT-3 cells. Phosphorothioate analogs penetrated and accumulated intact in cells in contrast to unmodified oligomers, which showed a high instability in cell culture medium. A slow decrease of intracellular concentration of undegraded phosphorothioate oligodeoxynucleotides was observed after cell treatment and could be predominantly explained by a significant efflux transport. Using laser-assisted confocal microscopy we have observed that fluorescein 5-end-labeled phosphorothioate derivatives predominantly distributed in intracytoplasmic endocytic vesicles following cell treatment. The end-capped version of phosphorothioate oligodeoxynucleotides exhibited greater cellular uptake than fully modified analogues while exhibiting similar biological stability. Liposome encapsulation made possible oligomer protection in serum-containing medium and substantially improved cellular accumulation. Furthermore, the efflux rate of oligomer initially introduced within liposomes is 2-fold lower than that observed in cells which have been incubated with free oligonucleotides. Liposomal preparations of oligodeoxynucleotides facilitate release from endocytic vesicles, and thus, cytoplasmic and nuclear localization are observed following cell treatment. Furthermore, intracellular distribution studies demonstrate that intracellular transport of unmodified oligomers is effectively achieved using the liposomal carrier.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. M. Furneri, M. Fresta, G. Puglisi, and G. Tempera Ofloxacin-Loaded Liposomes: In Vitro Activity and Drug Accumulation in Bacteria Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2458 - 2464. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. P. Claudio, M. Caputi, and A. Giordano The RB2/p130 Gene: The Latest Weapon in the War against Lung Cancer? Clin. Cancer Res., March 1, 2000; 6(3): 754 - 764. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Pagnan, D. D. Stuart, F. Pastorino, L. Raffaghello, P. G. Montaldo, T. M. Allen, B. Calabretta, and M. Ponzoni Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects J Natl Cancer Inst, February 2, 2000; 92(3): 253 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lorenz, T. Misteli, B. F. Baker, C. F. Bennett, and D. L. Spector Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides Nucleic Acids Res., January 15, 2000; 28(2): 582 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Romano, P. Micheli, C. Pacilio, and A. Giordano Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications Stem Cells, January 1, 2000; 18(1): 19 - 39. [Abstract] [Full Text]
|
|
|
|
|
|
G. Romano, C. Pacilio, and A. Giordano Gene Transfer Technology in Therapy: Current Applications and Future Goals Stem Cells, July 1, 1999; 17(4): 191 - 202. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Romano, C. Pacilio, and A. Giordano Gene Transfer Technology in Therapy: Current Applications and Future Goals Oncologist, August 1, 1998; 3(4): 225 - 236. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Lorenz, B. F. Baker, C. F. Bennett, and D. L. Spector Phosphorothioate Antisense Oligonucleotides Induce the Formation of Nuclear Bodies Mol. Biol. Cell, May 1, 1998; 9(5): 1007 - 1023. [Abstract] [Full Text]
|
|
|
|
|
|
R. Kronenwett, U. Steidl, M. Kirsch, G. Sczakiel, and R. Haas Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset Blood, February 1, 1998; 91(3): 852 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Bishop, J. K. Guy-Caffey, J. O. Ojwang, S. R. Smith, M. E. Hogan, P. A. Cossum, R. F. Rando, and N. Chaudhary Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide J. Biol. Chem., March 8, 1996; 271(10): 5698 - 5703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Lesh, A. P. Somlyo, G. K. Owens, and A. V. Somlyo Reversible Permeabilization : A Novel Technique for the Intracellular Introduction of Antisense Oligodeoxynucleotides Into Intact Smooth Muscle Circ. Res., August 1, 1995; 77(2): 220 - 230. [Abstract] [Full Text]
|
|